<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368105</url>
  </required_header>
  <id_info>
    <org_study_id>SilesianMUKB-647/2017</org_study_id>
    <nct_id>NCT03368105</nct_id>
  </id_info>
  <brief_title>Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain</brief_title>
  <official_title>Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantation Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to analyze whether the use of the LP299v strain reduces the risk of&#xD;
      Clostridium difficile infection (CDI) among patients receiving antibiotics and hospitalized&#xD;
      in the nephrology and transplantation ward.&#xD;
&#xD;
      Patients from risk group (receiving immunosuppressive drugs and treated with antibiotics)&#xD;
      were enrolled into study.&#xD;
&#xD;
      Participants will be divided into two groups. First group will receive one capsule of&#xD;
      Lactobacillus plantarum 299v (LP299v) orally per a day. Second group will receive placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clostridium difficile is currently the most frequently identified pathogen causing&#xD;
      antibiotic-associated diarrhoea and the main cause of nosocomial diarrhoea. In regard to&#xD;
      observed worldwide increase rate of infection and mortality from CDI the prevention of&#xD;
      Clostridium difficile infections seems to be crucial, especially in patients at CDI high&#xD;
      risk. So far, it has not been unambiguously proven that probiotics are effective in the&#xD;
      prevention of Clostridium difficile infection among patients undergoing antibiotic therapy.&#xD;
&#xD;
      The Lactobacillus plantarum 299v (LP299v) is a Gram-positive lactic acid bacteria that&#xD;
      naturally occurs on the surface of human intestinal mucosa. Specific properties to the gut&#xD;
      mucosa colonization are due to mannose-dependent adhesion of LP299v to the epithelium of&#xD;
      human intestines.This ability of LP299v leads to reduction of bacterial translocation from&#xD;
      the intestinal lumen into the blood vessels, can prevent adhesion of many pathogens to&#xD;
      intestinal epithelium and modulate the inflammatory response of the epithelium. The strain&#xD;
      299v of Lactobacillus plantarum has been found to decrease the severity of gastrointestinal&#xD;
      adverse effects during antibiotic therapy. Limited data are available regarding the efficacy&#xD;
      of LP299v for preventing Clostridium difficile infections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">January 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clostridium difficile infection</measure>
    <time_frame>During hospitalization - average of 14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Clostridium Difficile</condition>
  <arm_group>
    <arm_group_label>LP299v group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants: one capsule of LP299v orally per a day during the entire period of antibiotic therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants: one capsule of placebo orally per a day during the entire period of antibiotic therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prevention of C. difficile infections using LP299v strain</intervention_name>
    <description>Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.&#xD;
We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy.</description>
    <arm_group_label>LP299v group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  over 18 years old&#xD;
&#xD;
          -  organ transplantation or receiving immunosuppressive drugs for any other reasons&#xD;
&#xD;
          -  antibiotics therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no consent to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sylwia Dudzicz, MD</last_name>
    <phone>606305029</phone>
    <email>sylwia.dudzicz@gmail.com</email>
  </overall_contact>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile Infection</keyword>
  <keyword>Lactobacillus plantarum 299v</keyword>
  <keyword>organ transplantation</keyword>
  <keyword>antibiotic-associated diarrhoea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

